日本厚生劳动省-话题@MedSci

#日本厚生劳动省#

10篇内容 | 868人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1368749, encodeId=22801368e49ca, content=<a href='/topic/show?id=3e3f592287a' target=_blank style='color:#2F92EE;'>#日本厚生劳动省#</a>, objectTitle=日本厚生劳动省批准CAR-T细胞疗法Breyanzi治疗DLBCL和滤泡性淋巴瘤, objectType=article, longId=209158, objectId=40ec209158b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=40ec209158b9, replyNumber=0, likeNumber=37, createdTime=2021-03-31, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=40ec209158b9, moduleTitle=日本厚生劳动省批准CAR-T细胞疗法Breyanzi治疗DLBCL和滤泡性淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=40ec209158b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368748, encodeId=b2841368e48e6, content=<a href='/topic/show?id=3e3f592287a' target=_blank style='color:#2F92EE;'>#日本厚生劳动省#</a>, objectTitle=日本厚生劳动省（MHLW）批准ORLADEYO（贝罗司他）用于遗传性血管性水肿的预防性治疗, objectType=article, longId=206188, objectId=8ad420618870, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ad420618870, replyNumber=0, likeNumber=41, createdTime=2021-01-26, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ad420618870, moduleTitle=日本厚生劳动省（MHLW）批准ORLADEYO（贝罗司他）用于遗传性血管性水肿的预防性治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ad420618870)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368747, encodeId=96bc1368e47c6, content=<a href='/topic/show?id=3e3f592287a' target=_blank style='color:#2F92EE;'>#日本厚生劳动省#</a>, objectTitle=日本厚生劳动省（MHLW）批准α-1蛋白酶抑制剂Lynspad治疗α-1抗胰蛋白酶缺乏症, objectType=article, longId=206186, objectId=022b2061861a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=022b2061861a, replyNumber=0, likeNumber=38, createdTime=2021-01-26, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=022b2061861a, moduleTitle=日本厚生劳动省（MHLW）批准α-1蛋白酶抑制剂Lynspad治疗α-1抗胰蛋白酶缺乏症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=022b2061861a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368746, encodeId=01331368e462b, content=<a href='/topic/show?id=3e3f592287a' target=_blank style='color:#2F92EE;'>#日本厚生劳动省#</a>, objectTitle=日本厚生劳动省批准ravulizumab治疗成人和儿童非典型溶血性尿毒症综合征（aHUS）, objectType=article, longId=201254, objectId=80e12012542c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=80e12012542c, replyNumber=0, likeNumber=40, createdTime=2020-09-28, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=80e12012542c, moduleTitle=日本厚生劳动省批准ravulizumab治疗成人和儿童非典型溶血性尿毒症综合征（aHUS）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=80e12012542c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368745, encodeId=cf4a1368e451a, content=<a href='/topic/show?id=3e3f592287a' target=_blank style='color:#2F92EE;'>#日本厚生劳动省#</a>, objectTitle=日本厚生劳动省批准Vadadustat治疗慢性肾病引起的贫血, objectType=article, longId=196852, objectId=aa351968524c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa351968524c, replyNumber=0, likeNumber=41, createdTime=2020-07-02, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa351968524c, moduleTitle=日本厚生劳动省批准Vadadustat治疗慢性肾病引起的贫血, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa351968524c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368744, encodeId=99491368e4486, content=<a href='/topic/show?id=3e3f592287a' target=_blank style='color:#2F92EE;'>#日本厚生劳动省#</a>, objectTitle=日本厚生劳动省：授予tepotinib治疗MET基因改变的NSCLC患者的孤儿药认定, objectType=article, longId=183347, objectId=97cd18334e4f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97cd18334e4f, replyNumber=0, likeNumber=45, createdTime=2019-11-23, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97cd18334e4f, moduleTitle=日本厚生劳动省：授予tepotinib治疗MET基因改变的NSCLC患者的孤儿药认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=97cd18334e4f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368743, encodeId=53511368e4314, content=<a href='/topic/show?id=3e3f592287a' target=_blank style='color:#2F92EE;'>#日本厚生劳动省#</a>, objectTitle=日本厚生劳动省：授予Polatuzumab vedotin治疗弥漫性大B细胞淋巴瘤的孤儿药认定, objectType=article, longId=183346, objectId=525e183346c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=525e183346c6, replyNumber=0, likeNumber=44, createdTime=2019-11-23, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=525e183346c6, moduleTitle=日本厚生劳动省：授予Polatuzumab vedotin治疗弥漫性大B细胞淋巴瘤的孤儿药认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=525e183346c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368742, encodeId=3d6f1368e4284, content=<a href='/topic/show?id=3e3f592287a' target=_blank style='color:#2F92EE;'>#日本厚生劳动省#</a>, objectTitle=Daiichi Sankyo的EZH1/2双重抑制剂Valemetostat获得日本厚生劳动省SAKIGAKE指定，用于治疗复发/难治性外周T细胞淋巴瘤, objectType=article, longId=163986, objectId=5b4b163986c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b4b163986c0, replyNumber=0, likeNumber=35, createdTime=2019-04-11, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b4b163986c0, moduleTitle=Daiichi Sankyo的EZH1/2双重抑制剂Valemetostat获得日本厚生劳动省SAKIGAKE指定，用于治疗复发/难治性外周T细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b4b163986c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368741, encodeId=69891368e4189, content=<a href='/topic/show?id=3e3f592287a' target=_blank style='color:#2F92EE;'>#日本厚生劳动省#</a>, objectTitle=成纤维细胞生长因子受体酪氨酸激酶抑制剂E7090治疗胆管癌，获得日本厚生劳动省的Sakigake指定, objectType=article, longId=163899, objectId=93891638993f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93891638993f, replyNumber=0, likeNumber=33, createdTime=2019-04-10, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93891638993f, moduleTitle=成纤维细胞生长因子受体酪氨酸激酶抑制剂E7090治疗胆管癌，获得日本厚生劳动省的Sakigake指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93891638993f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1368740, encodeId=52bf1368e4087, content=<a href='/topic/show?id=3e3f592287a' target=_blank style='color:#2F92EE;'>#日本厚生劳动省#</a>, objectTitle=SanBio宣布其再生细胞疗法SB623治疗创伤性脑损伤，获得日本厚生劳动省Sakigake指定, objectType=article, longId=163898, objectId=0ea91638984f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ea91638984f, replyNumber=0, likeNumber=39, createdTime=2019-04-10, rootId=0, userName=839640778, userId=45b2276, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ea91638984f, moduleTitle=SanBio宣布其再生细胞疗法SB623治疗创伤性脑损伤，获得日本厚生劳动省Sakigake指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ea91638984f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

日本厚生劳动省

2020-05-29

839640778 (审核中...)

前往app查看评论内容

#日本厚生劳动省#

日本厚生劳动省批准CAR-T细胞疗法Breyanzi治疗DLBCL和滤泡性淋巴瘤

2021-03-31

839640778 (审核中...)

前往app查看评论内容

#日本厚生劳动省#

日本厚生劳动省（MHLW）批准ORLADEYO（贝罗司他）用于遗传性血管性水肿的预防性治疗

2021-01-26

839640778 (审核中...)

前往app查看评论内容

#日本厚生劳动省#

日本厚生劳动省（MHLW）批准α-1蛋白酶抑制剂Lynspad治疗α-1抗胰蛋白酶缺乏症

2021-01-26

839640778 (审核中...)

前往app查看评论内容

#日本厚生劳动省#

日本厚生劳动省批准ravulizumab治疗成人和儿童非典型溶血性尿毒症综合征（aHUS）

2020-09-28

839640778 (审核中...)

前往app查看评论内容

#日本厚生劳动省#

日本厚生劳动省批准Vadadustat治疗慢性肾病引起的贫血

2020-07-02

839640778 (审核中...)

前往app查看评论内容

#日本厚生劳动省#

日本厚生劳动省：授予tepotinib治疗MET基因改变的NSCLC患者的孤儿药认定

2019-11-23

839640778 (审核中...)

前往app查看评论内容

#日本厚生劳动省#

日本厚生劳动省：授予Polatuzumab vedotin治疗弥漫性大B细胞淋巴瘤的孤儿药认定

2019-11-23

839640778 (审核中...)

前往app查看评论内容

#日本厚生劳动省#

Daiichi Sankyo的EZH1/2双重抑制剂Valemetostat获得日本厚生劳动省SAKIGAKE指定，用于治疗复发/难治性外周T细胞淋巴瘤

2019-04-11

839640778 (审核中...)

前往app查看评论内容

#日本厚生劳动省#

成纤维细胞生长因子受体酪氨酸激酶抑制剂E7090治疗胆管癌，获得日本厚生劳动省的Sakigake指定

2019-04-10

839640778 (审核中...)

前往app查看评论内容

#日本厚生劳动省#

SanBio宣布其再生细胞疗法SB623治疗创伤性脑损伤，获得日本厚生劳动省Sakigake指定

2019-04-10

科室
- - 订阅+
  - 更多科室
工具
服务